The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rubtsov M.S.

Research Institute for Complex Problems of Cardiovascular Diseases, Kemerovo, Russia

Shukevich D.L.

Kemerovskaia oblastnaia klinicheskaia bol'nitsa

Modern extracorporeal methods for critical conditions caused by systemic inflammatory response (review)

Authors:

Rubtsov M.S., Shukevich D.L.

More about the authors

Journal: Russian Journal of Anesthesiology and Reanimatology. 2019;(4): 20‑30

DOI: 10.17116/anaesthesiology201904120

Read: 4368 times

Download PDF (RU)
Contact the author
Table of contents

MODERN EXTRACORPOREAL METHODS FOR CRITICAL CONDITIONS CAUSED BY SYSTEMIC INFLAMMATORY RESPONSE (REVIEW)
MODERN EXTRACORPOREAL METHODS FOR CRITICAL CONDITIONS CAUSED BY SYSTEMIC INFLAMMATORY RESPONSE (REVIEW)

To cite this article:

Rubtsov MS, Shukevich DL. Modern extracorporeal methods for critical conditions caused by systemic inflammatory response (review). Russian Journal of Anesthesiology and Reanimatology. 2019;(4):20‑30. (In Russ.)
https://doi.org/10.17116/anaesthesiology201904120

Подписка 2025-2 (АиР)
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata

ABSTRACT The study of elimination of inflammatory mediators using extracorporeal methods has become one of the most promising scientific directions because extracorporeal methods reduce clinical severity of systemic inflammatory response (SIR) and prevent multiple organ dysfunction. Modern extracorporeal methods for elimination of endotoxin and cytokines and decrease of SIR are reviewed in the article. First of all, extracorporeal methods with transmembrane mechanism of elimination due to convection and diffusion are considered. Technologies based on adsorption as one more basic mechanism of elimination are also analyzed. The strategies of extracorporeal blood purification presented in the review have been of the greatest scientific interest in recent years. There are advanced number of trials devoted to the effectiveness of these methods in patients in critical condition. However, evidence level is still considered trivial. These methods are still used depending on economic opportunities and accumulated clinical experience. In our opinion, further research will be useful to substantiate the effectiveness of targeted personalized approach to extracorporeal methods of treatment. These data may be essential for final recognition of extracorporeal treatment and provide further development of this approach and more optimistic prospects for patients.

Keywords:

systemic inflammatory response
sepsis
highly permeable membranes
cytokines
endotoxin
extracorporeal blood purification
hemosorption

Authors:

Rubtsov M.S.

Research Institute for Complex Problems of Cardiovascular Diseases, Kemerovo, Russia

Shukevich D.L.

Kemerovskaia oblastnaia klinicheskaia bol'nitsa

List of references:

  1. Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Critical Care. 2016;20(1):387. https://doi.org/10.1186/s13054-016-1570-4
  2. Barbarash LS, Grigoryev EV, Plotnikov GP, Shukevich DL, Shukevich LE. Hemodynamics and hydrodynamic status during renal replacement therapy in systemic inflammatory response syndrome of infectious or noninfectious etiology. Kompleksnye problemy serdechno-sosudistyh zabolevanij. 2012;2:39-44. (In Russ.) https://doi.org/10.17802/2306-1278-2012-2-39-44
  3. Villa G, Zaragoza JJ, Sharma A, Neri M, De Gaudio AR, Ronco C. Cytokine removal with high cut-off membrane: review of literature. Blood Purification. 2014;38(3-4):167-173. https://doi.org/10.1159/000369155
  4. Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, Ferrari F, Guggia S, Joannidis M, Kellum J, Kim JC, Mehta RL, Ricci Z, Trevisani A, Marafon S, Clark WR, Vincent JL, Ronco C; Nomenclature Standardization Initiative (NSI) alliance. Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Critical Care. 2016;20(1):318. https://doi.org/10.1186/s13054-016-1489-9
  5. Storr M, Ward RA. Membrane innovation: closer to native kidneys. Nephrology Dialysis Transplantation. 2018;33(Suppl 3):22-27. https://doi.org/10.1093/ndt/gfy228
  6. Honore PM, Spapen HD. What a clinician should know about a renal replacement membrane? Journal of Translational Internal Medicine. 2018;6(2):62-65. https://doi.org/10.2478/jtim-2018-0016
  7. Ronco C, Marchionna N, Brendolan A, Neri M, Lorenzin A, Martínez Rueda AJ. Expanded haemodialysis: from operational mechanism to clinical results. Nephrology Dialysis Transplantation. 2018;33(Suppl 3):41-47. https://doi.org/10.1093/ndt/gfy202
  8. Boschetti-de-Fierro A, Voigt M, Storr M, Krause B. Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. International Journal of Artificial Organs. 2013;36:455-463. https://doi.org/10.5301/ijao.5000220
  9. Naka T, Haase M, Bellomo R. «Super high-flux» or «high cut-off» hemofiltration and hemodialysis. Contributions to Nephrology. 2010;166:181-189. https://doi.org/10.1159/000314871
  10. Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, Boer W, Verfaillie L, Spapen HD. Newly designed CRRT membranes for sepsis and SIRS — a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO Journal. 2013;59(2):99-106. https://doi.org/10.1097/MAT.0b013e3182816a75
  11. Villa G, Zaragoza JJ, Sharma A, Chelazzi C, Ronco C, De Gaudio AR. High cutoff membrane to reduce systemic inflammation due to differentiation syndrome: a case report. Blood Purification. 2014;38(3-4):234-238. https://doi.org/10.1159/000369379
  12. Chelazzi C, Villa G, D’Alfonso MG, Mancinelli P, Consales G, Berardi M, De Gaudio AR, Romagnoli S. Hemodialysis with high cut-off hemodialyzers in patients with multi-drug resistant Gram-negative sepsis and acute kidney injury: a retrospective, case-control study. Blood Purification. 2016;42(3):186-193. https://doi.org/10.1159/000446978
  13. Villa G, Chelazzi C, Morettini E, Zamidei L, Valente S, Caldini AL, Zagli G, De Gaudio AR, Romagnoli S. Organ dysfunction during continuous veno-venous high cut-off hemodialysis in patients with septic acute kidney injury: A prospective observational study. PLoS One. 2017;12(2):e0172039. https://doi.org/10.1371/journal.pone.0172039
  14. Kade G, Lubas A, Rzeszotarska A, Korsak J, Niemczyk S. Effectiveness of high cut-off hemofilters in the removal of selected cytokines in patients during septic shock accompanied by acute kidney injury-preliminary study. Medical Science Monitor. 2016;22:4338-4344. https://doi.org/10.12659/MSM.896819
  15. Eichhorn T, Hartmann J, Harm S, Linsberger I, König F, Valicek G, Miestinger G, Hörmann C, Weber V. Clearance of selected plasma cytokines with continuous veno-venous hemodialysis using Ultraflux EMiC2 versus Ultraflux AV1000S. Blood Purification. 2017;44(4):260-266. https://doi.org/10.1159/000478965
  16. Kade G, Literacki S, Rzeszotarska A, Niemczyk S, Lubas A. Removal of procalcitonin and selected cytokines during continuous veno-venous hemodialysis using High Cutoff Hemofilters in patients with sepsis and acute kidney injury. Blood Purification. 2018;46(2):153-159. https://doi.org/10.1159/000488929
  17. Masakane I, Sakurai K. Current approaches to middle molecule removal: room for innovation. Nephrology Dialysis Transplantation. 2018;33(Suppl 3). https://doi.org/10.1093/ndt/gfy224
  18. Abe T, Kato K, Fujioka T, Akizawa T. The blood compatibilities of blood purification membranes and other materials developed in Japan. International Journal of Biomaterials. 2011;2011:375390. https://doi.org/10.1155/2011/375390
  19. Thomas M, Moriyama K, Ledebo I. AN69: evolution of the world’s first high permeability membrane. Contributions to Nephrology. 2011;173:119-129. https://doi.org/10.1159/000328961
  20. Doi K, Iwagami M, Yoshida E, Marshall MR. Associations of Polyethylenimine-Coated AN69ST Membrane in Continuous Renal Replacement Therapy with the Intensive Care Outcomes: Observations from a Claims Database from Japan. Blood Purification. 2017;44(3):184-192. https://doi.org/10.1159/000476052
  21. Yumoto M, Nishida O, Moriyama K, Shimomura Y, Nakamura T, Kuriyama N, Hara Y, Yamada S. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Therapeutic Apheresis and Dialysis. 2011;15(4):385-393. https://doi.org/10.1111/j.1744-9987.2011.00971.x
  22. Hirayama Y, Oda S, Wakabayashi K, Sadahiro T, Nakamura M, Watanabe E, Tateishi Y. Comparison of interleukin-6 removal properties among hemofilters consisting of varying membrane materials and surface areas: an in vitro study. Blood Purification. 2011;31(1-3):18-25. https://doi.org/10.1159/000321142
  23. Ooishi Y, Ishii T, Takahata T, Inagaki N, Akizuki N, Isakozawa Y, Takesawa S, Hirasawa H. Efficacy of series double continuous hemodiafiltration using two polymethyl methacrylate membrane hemofilters for patients with hypercytokinemia. Therapeutic Apheresis and Dialysis. 2014;18(2):132-139. https://doi.org/10.1111/1744-9987.12075
  24. Yamashita AC, Tomisawa N. Membrane materials for blood purification in critical care. Contributions to Nephrology. 2010;166:112-118. https://doi.org/10.1159/000314859
  25. Yamashita AC, Tomisawa N. Which solute removal mechanism dominates over others in dialyzers for continuous renal replacement therapy? Hemodialysis International. 2010;14 (Suppl 1):S7-13. https://doi.org/10.1111/j.1542-4758.2010.00484.x
  26. Shiga H, Hirasawa H, Nishida O, Oda S, Nakamura M, Mashiko K, Matsuda K, Kitamura N, Kikuchi Y, Fuke N. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock: a preliminary report. Blood Purification. 2014;38(3-4):211-218. https://doi.org/10.1159/00036937
  27. Kobashi S, Maruhashi T, Nakamura T, Hatabayashi E, Kon A. The 28-day survival rates of two cytokine-adsorbing hemofilters for continuous renal replacement therapy: a single-center retrospective comparative study. Acute Medicine and Surgery. 2018;6(1):60-67. https://doi.org/10.1002/ams2.382
  28. Minematsu Y, Yamato M, Ikemiya Y, Ito T. The superiority of AN69ST membrane in the adsorption of fibroblast growth factor 23. Clinical Laboratory. 2016;62:219-225.
  29. Yamato M, Minematsu Y, Ikemiya Y, Shibata J, Fujii J, Minato T, Miyagawa S, Takaori K, Tomiyama Y, Nagayama I, Wada A, Ito T, Iwatani H. Continuous Hemodiafiltration with an AN69ST Hemofilter (AN69ST-CHDF) as FGF-23-Lowering Therapy. Clinical Laboratory. 2016;62(12):2349-2354. https://doi.org/10.7754/Clin.Lab.2016.160423
  30. Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Medicine Experimental. 2018;6(1):12. https://doi.org/10.1186/s40635-018-0177-2
  31. Feri M. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices: a misleading article for clinical practice? Intensive Care Medicine Experimental. 2019;7(1):5. https://doi.org/10.1186/s40635-018-0214-1
  32. Sakai Y. Polymethylmethacrylate membrane with a series of serendipity. Contributions to Nephrology. 2011;173:137-147. https://doi.org/10.1159/000329052
  33. Hirasawa H. Indications for blood purification in critical care. Contributions to Nephrology. 2010;166:21-30. https://doi.org/10.1159/000314847
  34. Hirasawa H, Oda S, Nakamura M, Watanabe E, Shiga H, Matsuda K. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter for sepsis. Blood Purification. 2012;34(2):164-170. https://doi.org/10.1159/000342379
  35. Nakamura M, Oda S, Sadahiro T, Hirayama Y, Watanabe E, Tateishi Y, Nakada TA, Hirasawa H. Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. Contributions to Nephrology. 2010;166:73-82. https://doi.org/10.1159/000314855
  36. Taniguchi T. Cytokine adsorbing columns. Contributions to Nephrology. 2010;166:134-141. https://doi.org/10.1159/000314863
  37. Hinz B, Jauch O, Noky T, Friesecke S, Abel P, Kaiser R. CytoSorb, a novel therapeutic approach for patients with septic shock: a case report. International Journal of Artificial Organs. 2015;38(8):461-464. https://doi.org/10.5301/ijao.5000429
  38. Bruenger F, Kizner L, Weile J, Morshuis M, Gummert JF. First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. International Journal of Artificial Organs. 2015;38(2):113-116. https://doi.org/10.5301/ijao.5000382
  39. Träger K, Fritzler D, Fischer G, Schröder J, Skrabal C, Liebold A, Reinelt H. Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series. International Journal of Artificial Organs. 2016;39(3):141-146. https://doi.org/10.5301/ijao.5000492
  40. Träger K, Skrabal C, Fischer G, Datzmann T, Schroeder J, Fritzler D, Hartmann J, Liebold A, Reinelt H. Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass — a case series. International Journal of Artificial Organs. 2017;40(5):240-249. https://doi.org/10.5301/ijao.5000583
  41. Steltzer H, Grieb A, Mostafa K, Berger R. Use of CytoSorb in Traumatic Amputation of the Forearm and Severe Septic Shock. Case Reports in Critical Care. 2017;2017:8747616. https://doi.org/10.1155/2017/8747616
  42. Shukevich DL, Plotnikov GP, Rubtsov MS, Matveeva VG, Grigor'ev EV. The first experience of the sorption of cytokines in patients with sepsis after cardiac surgery. Vestnik intensivnoj terapii. 2016;4:59-61.
  43. Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: a case series. Critical Care. 2017;21(1):74. https://doi.org/10.1186/s13054-017-1662-9
  44. Friesecke S, Stecher SS, Gross S, Felix SB, Nierhaus A. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. International Journal of Artificial Organs. 2017;20(3):252-259. https://doi.org/10.1007/s10047-017-0967-4
  45. Friesecke S, Träger K, Schittek GA, Molnar Z, Bach F, Kogelmann K, Bogdanski R, Weyland A, Nierhaus A, Nestler F, Olboeter D, Tomescu D, Jacob D, Haake H, Grigoryev E, Nitsch M, Baumann A, Quintel M, Schott M, Kielstein JT, Meier-Hellmann A, Born F, Schumacher U, Singer M, Kellum J, Brunkhorst FM. International registry on the use of the CytoSorb® adsorber in ICU patients. Medizinische Klinik, Intensivmedizin und Notfallmedizin. 2017 Sep 4. Epub ahead of print. https://doi.org/10.1007/s00063-017-0342-5
  46. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810. https://doi.org/10.1001/jama.2016.0287
  47. Ankawi G, Neri M, Zhang J, Breglia A, Ricci Z, Ronco C. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Critical Care. 2018;22(1):262. https://doi.org/10.1186/s13054-018-2181-z
  48. Ronco C. Endotoxin removal: history of a mission. Blood Purification. 2014;3 (Suppl 1):5-8. https://doi.org/10.1159/000356831
  49. Shimizu T, Miyake T, Tani M. History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock. Annals of Gastroenterological Surgery. 2017;1(2):105-113. https://doi.org/10.1002/ags3.12015
  50. Ronco C, Klein DJ. Polymyxin B hemoperfusion: a mechanistic perspective. Critical Care. 2014;18(3):309. https://doi.org/10.1186/cc13912
  51. Shimizu T, Miyake T, Kitamura N, Tani M, Endo Y. Endotoxin adsorption: Direct hemoperfusion with the polymyxin B-immobilized fiber column (PMX). Transfusion and Apheresis Science. 2017;56(5):682-688. https://doi.org/10.1016/j.transci.2017.08.015
  52. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445-2452. https://doi.org/10.1001/jama.2009.856
  53. Martin EL, Cruz DN, Monti G, Casella G, Vesconi S, Ranieri VM, Ronco C, Antonelli M. Endotoxin removal: how far from the evidence? The EUPHAS 2 Project. Contributions to Nephrology. 2010;167:119-125. https://doi.org/10.1159/000315926
  54. Cutuli SL, Artigas A, Fumagalli R, Monti G, Ranieri VM, Ronco C, Antonelli M; EUPHAS 2 Collaborative Group. Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Annals of Intensive Care. 2016;6(1):77. https://doi.org/10.1186/s13613-016-0178-9
  55. Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, Mimoz O, Coudroy R, Ferrandière M, Kipnis E, Vela C, Chevallier S, Mallat J, Robert R; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Medicine. 2015;41(6):975-984. https://doi.org/10.1007/s00134-015-3751-z
  56. Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials. 2014;15:218. https://doi.org/10.1186/1745-6215-15-218
  57. Chang T, Tu YK, Lee CT, Chao A, Huang CH, Wang MJ, Yeh YC. Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Critical Care Medicine. 2017;45(8):e858-e864. https://doi.org/10.1097/CCM.0000000000002362
  58. Iba T, Fowler L. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. Journal of Intensive Care. 2017;5:40. https://doi.org/10.1186/s40560-017-0236-x
  59. Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, Palevsky PM, Weisberg LS, Schorr CA, Trzeciak S, Walker PM; EUPHRATES Trial Investigators. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA. 2018;320(14):1455-1463. https://doi.org/10.1001/jama.2018.14618
  60. Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Medicine. 2018;44(12):2205-2212. https://doi.org/10.1007/s00134-018-5463-7
  61. Ilia S, Briassoulis P, Briassoulis G. Polymyxin B hemoperfusion in septic shock: nothing overmuch (Meden Agan)! Journal of Thoracic Disease. 2017;9(9):2716-2719. https://doi.org/10.21037/jtd.2017.08.106
  62. Honore PM, De Bels D, Preseau T, Redant S, Spapen HD. Efficacy of polymyxin B hemoperfusion in and beyond septic shock: is an «endotoxin severity score» needed? Critical Care. 2018;22(1):205. https://doi.org/10.1186/s13054-018-2093-y
  63. Iwagami M, Yasunaga H, Noiri E, Horiguchi H, Fushimi K, Matsubara T, Yahagi N, Nangaku M, Doi K. Potential Survival Benefit of Polymyxin B Hemoperfusion in Septic Shock Patients on Continuous Renal Replacement Therapy: A Propensity-Matched Analysis. Blood Purification. 2016;42(1):9-17. https://doi.org/10.1159/000444474
  64. Lee CT, Tu YK, Yeh YC, Chang T, Shih PY, Chao A, Huang HH, Cheng YJ, Yeh YC; Behalf of the NTUH Center of Microcirculation Medical Research (NCMMR). Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shock patients. Journal of Critical Care. 2018;43:202-206. https://doi.org/10.1016/j.jcrc.2017.04.035
  65. Nakamura Y, Kitamura T, Kiyomi F, Hayakawa M, Hoshino K, Kawano Y, Yamasaki R, Nishida T, Mizunuma M, Ishikura H; Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study group. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study. Critical Care. 2017;21(1):134. https://doi.org/10.1186/s13054-017-1712-3
  66. Terayama T, Yamakawa K, Umemura Y, Aihara M, Fujimi S. Polymyxin B Hemoperfusion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Surgical Infections. 2017;18(3):225-233. https://doi.org/10.1089/sur.2016.168
  67. Kuriyama A, Katsura M, Urushidani S, Takada T. Impact of polymyxin B hemoperfusion in the treatment of patients with sepsis and septic shock: a meta-analysis of randomized controlled trials. Annals of Translational Medicine. 2018;6(11):206. https://doi.org/10.21037/atm.2018.05.41
  68. Fujii T, Ganeko R, Kataoka Y, Furukawa T.A, Featherstone R, Doi K, Vincent JL, Pasero D, Robert R, Ronco C, Bagshaw SM. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Medicine. 2018;44(2):167-178. https://doi.org/10.1007/s00134-017-5004-9
  69. Nishida O, Ogura H, Egi M, Fujishima S, Hayashi Y, Iba T, Imaizumi H, Inoue S, Kakihana Y, Kotani J1, Kushimoto S, Masuda Y, Matsuda N, Matsushima A, Nakada TA, Nakagawa S, Nunomiya S, Sadahiro T, Shime N, Yatabe T, Hara Y, Hayashida K, Kondo Y, Sumi Y, Yasuda H, Aoyama K, Azuhata T, Doi K, Doi M, Fujimura N, Fuke R, Fukuda T, Goto K, Hasegawa R, Hashimoto S, Hatakeyama J, Hayakawa M, Hifumi T, Higashibeppu N, Hirai K, Hirose T, Ide K, Kaizuka Y, Kan’o T, Kawasaki T, Kuroda H, Matsuda A, Matsumoto S, Nagae M, Onodera M, Ohnuma T, Oshima K, Saito N, Sakamoto S, Sakuraya M, Sasano M, Sato N, Sawamura A, Shimizu K, Shirai K, Takei T, Takeuchi M, Takimoto K, Taniguchi T, Tatsumi H, Tsuruta R, Yama N, Yamakawa K, Yamashita C, Yamashita K, Yoshida T, Tanaka H, Oda S. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). Journal of Intensive Care. 2018;6:7. https://doi.org/10.1186/s40560-017-0270-8
  70. Spectral Announces Approval of Tigris Trial by the US FDA. Available at: https://www.globenewswire.com/news-release/2019/02/19/1734223/0/en/Spectral-Announces-Approval-of-Tigris-Trial-by-the-US-FDA.html Accessed May 15, 2019.
  71. Nishibori M, Takahashi HK, Katayama H, Mori S, Saito S, Iwagaki H, Tanaka N, Morita K, Ohtsuka A. Specific Removal of Monocytes from Peripheral Blood of Septic Patients by Polymyxin B-immobilized Filter Column. Acta Medica Okayama. 2009;63(1):65-69. https://doi.org/10.18926/AMO/31855
  72. Kumagai T, Takeyama N, Yabuki T, Harada M, Miki Y, Kanou H, Inoue S, Nakagawa T, Noguchi H. Apheresis of activated leukocytes with an immobilized polymyxin B filter in patients with septic shock. Shock. 2010;34(5):461-466. https://doi.org/10.1097/SHK.0b013e3181e14ca0
  73. Yaroustovsky M, Abramyan M, Popok Z, Nazarova E, Stupchenko O, Popov D, Plushch M, Samsonova N. Preliminary report regarding the use of selective sorbents in complex cardiac surgery patients with extensive sepsis and prolonged intensive care stay. Blood Purification. 2009;28(3):227-233. https://doi.org/10.1159/000231988
  74. Ala-Kokko TI, Laurila J, Koskenkari J. A new endotoxin adsorber in septic shock: Observational case series. Blood Purification. 2011;32(4):303-309. https://doi.org/10.1159/000330323
  75. Adamik B, Zielinski S, Smiechowicz J, Kübler A. Endotoxin elimination in patients with septic shock: an observation study. Archivum Immunologiae et Therapiae Experimentalis. 2015;63(6):475-483. https://doi.org/10.1007/s00005-015-0348-8
  76. Loginov SP, Gromova EG, Kiselevskij MV, Krotenko NP, Doljikova JI, Vlasenko RJ, Kuznetsova LS. LPS-adsorber in patients with septic shock. The bulletin of intensive therapy named after A.I. Saltanov. 2018;3:46-52. https://doi.org/10.21320/1818-474X-2018-3-46-52.
  77. Zaitsev RR, Yakovlev AY, Abramov AV, Ryabikov DV, Chistyakov SI, Ilyin YV. Selective sorption of endotoxin in the complex therapy of posttraumatic abdominal sepsis. The bulletin of intensive therapy named after A.I. Saltanov.2017;2:21-25.
  78. Lipcsey M, Tenhunen J, Sjölin J, Frithiof R, Bendel S, Flaatten H, Kawati R, Kuitunen A, Tønnessen T, Rubertsson S. Abdominal Septic Shock — Endotoxin Adsorption Treatment (ASSET) — endotoxin removal in abdominal and urogenital septic shock with the Alteco® LPS Adsorber: study protocol for a double-blinded, randomized placebo-controlled trial. Trials. 2016;17(1):587. https://doi.org/10.1186/s13063-016-1723-4.
  79. Yarustovsky MB, Rogalskaya EA, Plyushch MG, Klimovich LG, Samsonova NN, Abramyan MV. Diagnostic value of neutrophil oxidative response during the endotoxin activity assay in patients with sepsis in intensive care units. Anesteziologiya i reanimatologiya. 2018;63(2):142-147. (In Russ.) https://doi.org/10.18821/0201-7563-2018-63-2-142-147
  80. Gendel LL, Sokolov AA, Gubanova SN, Adamova IYu, Levashov PA. First clinical experience of using column for lps-adsorption of toxipak in treatment of sepsis patients. Vestnik anesteziologii i reanimatologii. 2017;14(5):42-50. (In Russ.) https://doi.org/10.21292/2078-5658-2017-14-5-42-50
  81. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nature Reviews. Immunology. 2013;13(12):862-874. https://doi.org/10.1038/nri3552
  82. Rimmelé T, Payen D, Cantaluppi V, Marshall J, Gomez H, Gomez A, Murray P, Kellum JA; ADQI XIV Workgroup. Immune cell phenotype and function in sepsis. Shock. 2016;45(3):282-291. https://doi.org/10.1097/SHK.0000000000000495
  83. Khoroshilov SE, Nikulin AV. Detoxication in critical conditions: an insight into the scientific problem in the XXI century (review). Obshchaya reanimatologiya. 2017;13(5):85-108. (In Russ.) https://doi.org/10.15360/1813-9779-2017-5-85-108
  84. http://desepta-sorb.com/wp-content/uploads/2017/05/III-Conference-of-the-National-Society-THERAPEUTIC-HAEMAPHERESIS-AND-BLOOD-PUFICATION-2017.pdf

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.